# PHARMACEUTICALS

## **TNX-102 SL** Fibromyalgia, Long COVID, and Acute Stress Disorder

## NASDAQ: TNXP

Version P0568 May 22, 2024 (Doc 1435)

# Tonmya<sup>™</sup> (TNX-102 SL)\* Cyclobenzaprine HCI (Protectic<sup>®</sup>)

#### Non-opiate analgesic

A unique, sublingual formulation of cyclobenzaprine designed for bedtime dosing with sublingual delivery and transmucosal absorption, bypassing 1<sup>st</sup> pass metabolism

Potent binding and antagonist activities at the serotonergic-5-HT<sub>2A</sub>, adrenergic- $\alpha_1$ , histaminergic-H<sub>1</sub>, and muscarinic-M<sub>1</sub> cholinergic receptors to facilitate restorative sleep

Innovative and proprietary PROTECTIC<sup>®</sup> Rapid drug exposure following once nightly sublingual administration

#### **Differentiators:**

#### Relative to Oral Cyclobenzaprine

- Lower daytime exposure
- Avoids first-pass metabolism
- Reduces risk of pharmacological interference from major metabolite

#### **Relative to Standard of Care**

- Potential for better tolerability while maintaining efficacy
- Not scheduled, without recognized abuse potential



#### Fibromyalgia

Status: Two statistically significant Phase 3 studies completed

- First pivotal Phase 3 study (RELIEF) completed
- Second Phase 3 study (RALLY) missed primary endpoint
- Confirmatory pivotal Phase 3 study (RESILIENT) completed
   Next Steps: Type B Pre-NDA meeting with FDA scheduled
   for 2Q 2024

## Fibromyalgia-Type Long COVID

#### Status: Phase 2

- Phase 2 study (PREVAIL) completed
- Topline results reported 3Q 2023

**Next Steps:** Meeting with FDA regarding primary endpoint

### Acute Stress Reaction/ Acute Stress Disorder

- Phase 2 ready investigator-initiated study
- Department of Defense funded/ UNC will perform study
   Next Steps: Expect to start Phase 2 in 2Q 2024



#### Patents Issued

\*TNX-102 SL has not been approved for any indication.

## **About Fibromyalgia**

Fibromyalgia is a <u>chronic pain disorder</u> resulting from amplified sensory and pain signaling within the CNS<sup>1</sup>

*Fibromyalgia is a <u>syndrome</u> comprised of the symptoms: chronic widespread pain, nonrestorative sleep, and fatigue* 



Fibromyalgia is considered a chronic overlapping pain condition (COPC) - the only COPC with any FDA-approved drugs<sup>3</sup>

Fibromyalgia is the prototypic nociplastic syndrome



## Fibromyalgia is a Large, Underserved and Dissatisfied population

- ~10 million U.S. adults are affected predominantly women<sup>1,2</sup>
  - Debilitating and life altering condition
  - Significant economic cost

### • Patients are dissatisfied, despite three FDA approved drugs<sup>3,4</sup>

- Average patient has 20 physician office visits per year<sup>2</sup>
- Typical for patients to rotate between drugs<sup>3</sup>
- Polypharmacy (multiple drugs at the same time) common<sup>3</sup>
- Estimated that >22 million prescriptions are issued for the treatment of fibromyalgia (on- and offlabel usage) each year<sup>5,6</sup>

## Prescription opiate use declining because of availability

- Unknown number of patients using 'street drugs'
- No new Rx product since 2009


<sup>1</sup>American College of Rheumatology (<u>www.ACRPatientInfo.org</u> accessed May 7, 2019) – prevalence rate of 2-4% for U.S. adult population (~250 million) <sup>2</sup>Vincent A, et al. *Arthritis Care Res (Hoboken)*. 2013 65(5):786-92. doi: 10.1002; diagnosed prevalence rate was 1.1% of adult population or 50% of the prevalent population <sup>3</sup>Robinson RL, et al. *Pain Med*. 2012 13(10):1366-76. doi: 10.1111; ; 85% received drug treatment <sup>4</sup>The three drugs with FDA approval for the treatment of fibromyalgia: Pregabalin (Lyrica); Duloxetine (Cymbalta); Milnacipran (Savella) <sup>5</sup>Product sales derived from IMS MIDAS; IMS NDTI used to factor usage for fibromyalgia; data accessed April 2015. <sup>6</sup>Market research by Frost & Sullivan, commissioned by Tonix, 2011



## J.F.F.

## Poor Sleep and Pain have Bi-directional Reinforcing Effects<sup>1</sup>

- Poor sleep and pain form a vicious cycle in driving fibromyalgia decompensation
  - Can't sleep  $\rightarrow$  worse pain / In pain  $\rightarrow$  can't sleep
  - · Poor sleep and pain contribute to persistence, chronicity and severity
  - Syndrome includes symptoms of fatigue and brain fog
- Treating sleep disturbance in fibromyalgia has the potential to break the vicious cycle
  - Potential to remove an obstacle to recovery
  - Using the right medicine is important some sedative/hypnotics don't work<sup>1,2</sup>



## Fibromyalgia: Unrefreshing Sleep and Cyclobenzaprine Treatment

- Non-restorative sleep<sup>1,2</sup>
  - Harvey Moldofsky recognition of unrefreshing/non-restorative sleep:
    - Symptom
    - Potential causative or potentiating factor
- Cyclobenzaprine<sup>3,9</sup>
  - Potentially the earliest drug studied in fibromyalgia as an oral swallowed agent
  - Studies showed equivocal effects and tolerability issues at "muscle spasm" doses
- Bedtime, <u>low-dose</u> cyclobenzaprine targeting non-restorative sleep<sup>10-11</sup>
  - Recognition of unrefreshing sleep as a target of therapy
  - Primitive oral, swallowed formulation "flat" pharmacokinetics

#### Bedtime, <u>sublingual transmucosal</u> cyclobenzaprine targeting non-restorative sleep<sup>12</sup>

- Dynamic pharmacokinetic profile, rapid absorption, decrease in major metabolite
- Two studies (Phase 2 and Phase 3) at 2.8 mg; three Phase 3 studies at 5.6 mg.

<sup>1</sup>Moldofsky H et al. *Psychosom Med.* 1975. 37:341-51.
<sup>2</sup>Moldofsky H and Scarisbrick P. *Psychosom Med.* 1976. 38:35-44.
<sup>3</sup>Bennett RM, et al. *Arthritis Rheum* 1988. 31:1535–42.
<sup>4</sup>Quimby LG, et al. *J Rheumatol Suppl*, 1989 Nov;19:140–3.
<sup>5</sup>Reynolds WJ, et al. *J Rheumatol.* 1991.18:452–4.
<sup>6</sup>Santandrea S, et al. *J Int Med Res.* 1993.21:74–80.

<sup>7</sup>Cantini F, et al. *Minerva Med.* 1994. 85:97–100.
<sup>8</sup>Carette S, et al. *Arthritis Rheum.* 1994. 37:32–40.
<sup>9</sup>Tofferi JK, et al. *Arthritis Rheum.* 2004. 51:9–13.1
<sup>10</sup>Iglehart IW. 2003; US Patent 6,541,523.
<sup>11</sup>Moldofsky et al. *J Rheumatol.* 2011. 38:2653-2663
<sup>12</sup>Lederman S et al. *Arthritis Care Res.* 2023. 75:2359-2368.



## Fibromyalgia Program Status

Tonmya™\* (TNX-102 SL)

Fibromyalgia

Statistically Significant 2<sup>nd</sup> Phase 3 Topline Results Reported 4Q'23

Cyclobenzaprine Protectic® Sublingual Tablets

First pivotal Phase 3 study (RELIEF) reported – December 20201

Second Phase 3 study (RALLY) missed primary endpoint – July 2021

Confirmatory pivotal Phase 3 study (RESILIENT) reported – December 2023

**Next Steps:** 

- Type B Pre-NDA meeting scheduled with FDA in 2Q'24
- NDA filing expected 2H'24
- FDA decision on NDA approval expected 2H'25

\*Tonmya<sup>™</sup> is conditionally accepted by the U.S. Food and Drug Administration (FDA) as the tradename for TNX-102 SL for the management of fibromyalgia. Tonmya has not been approved for any indication.

<sup>1</sup>Lederman S, et al. Arthritis Care Res (Hoboken). 2023 Nov;75(11):2359-2368. doi: 10.100 2024 Tonix Pharmaceuticals Holding Corp.



RESI

## Tonmya<sup>™</sup> (TNX-102 SL): Phase 3 *RESILIENT* Study Design

#### **General study characteristics:**

- Randomized, double-blind, multicenter, placebo-controlled study in fibromyalgia
- 33 U.S. sites enrolled 457 participants with fibromyalgia as defined by 2016 Revisions to the 2010/2011 FM Diagnostic Criteria<sup>1</sup>

#### **Primary Endpoint:**

- Change from baseline to Week 14 (TNX-102 SL vs. placebo) in weekly averages of daily diary average pain severity score
- *Primary Endpoint, p-value = 0.00005*

<b>TNX-102 SL once-daily at bedtime</b> 5.6 mg (2 x 2.8 mg tablets)*	Clinic: Study
Placebo once-daily at bedtime	Taken Trial I
14 weeks	ł

\*Two-week run-in at 2.8 mg dose at bedtime followed by 12 weeks at 5.6 mg dose ClinicalTrials.gov Identifier: NCT05273749

Study Title: A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With Fibromyalgia (RESILIENT) Trial ID: TNY-CY-F307 ('RESILIENT')





© 2024 Tonix Pharmaceuticals Holding Corp.

## **RESILIENT** Summary of Endpoints





9

Endpoint	P-value	Effect Size (ES)
Primary Endpoint		
Daily Diary Pain ratings	<i>p</i> = 0.00005	ES = 0.38
Key Secondary Endpoints		
Patient Global Impression of Change (PGIC), responders	<i>p</i> = 0.00013	
Fibromyalgia Impact Questionnaire – Symptoms domain	<i>p</i> = 0.000002	ES = 0.44
Fibromyalgia Impact Questionnaire – Function domain	<i>p</i> = 0.001	ES = 0.30
PROMIS Sleep Disturbance instrument	<i>p</i> = 0.0000001	ES = 0.50
PROMIS Fatigue instrument	<i>p</i> = 0.00009	ES = 0.37
Diary Sleep Quality ratings	<i>p</i> = 0.0007	ES = 0.32


\*In order of statistical serial gate-keeping hierarchy (or, "waterfall") to control overall Type 1 error \*\*Statistical significance met



## **RESILIENT Primary Outcome Measure** *Reduction in Widespread Pain*



## Weekly Average of Daily Diary NRS Ratings of Average Pain Over Prior 24 Hours




Week 14 LS mean (SE) change from baseline for TNX-102 SL -1.82 (0.12) and for placebo -1.16 (0.12); LSMD from placebo -0.65 (0.16); p=0.00005<sup>#</sup>

\*Based on Mixed Model Repeated Measures with Multiple Imputation, with fixed categorical effects of treatment, center, study week, and treatment by study week interaction, as well as baseline value and baseline value-by-study week interaction. Abbreviations: LS, least squares; LSMD, least squares mean difference; NRS, numerical rating scale; SE, standard error





## **RESILIENT** Continuous Pain Responder Graph



#Analyses: Pearson's Chi Squared test for equality of proportions Abbreviations: CI, confidence interval; DIP, difference in proportions ^pre-specified analyses but not key secondary analyses


TONIX PHARMACEUTICALS

11

## **RESILIENT** Patient Global Impression of Change Key Secondary Outcome Measure



## Patient Global Impression of Change Responder Analysis



\*p<0.01; \*\*p<0.001

Week 14 TNX-102 SL responders 35.1%, and placebo responders 19.1%; difference in proportions (95% CI) 16% (7.9%, 24.0%); p=0.00013\*


<sup>#</sup>Based on a Pearson Chi-Squared with differences in proportions 95% CIs from difference in proportions Z-test Responders defined as subject that reply 'very much improved' or 'much improved' at Week 14; all others are non-responders CI, confidence interval



© 2024 Tonix Pharmaceuticals Holding Corp.

## **RESILIENT FIQ-R Symptoms Domain** Key Secondary Outcome Measure





Week 14 LS mean (SE) change from baseline for TNX-102 SL -16.0 (1.17) and for placebo -8.4 (1.17); LSMD from placebo -7.7 (1.62); p=0.000002\*

<sup>#</sup>Based on Mixed Model Repeated Measures with Multiple Imputation, with fixed categorical effects of treatment, center, study week, and treatment by study week interaction, as well as baseline value and baseline value-by-study week interaction.




## **RESILIENT FIQ-R Function Domain** Key Secondary Outcome Measure









Week 14 LS mean (SE) change from baseline for TNX-102 SL -12.2 (1.19) and for placebo -6.8 (1.21); LSMD from placebo -5.4 (1.66); p=0.001\*


\*Based on Mixed Model Repeated Measures with Multiple Imputation, with fixed categorical effects of treatment, center, study week, and treatment by study week interaction, as well as baseline value and baseline value-by-study week interaction.



14

## **RESILIENT PROMIS Sleep Disturbance Inventory** Key Secondary Outcome Measure






Week 14 LS mean (SE) change from baseline for TNX-102 SL -8.4 (0.57) and for placebo -4.2 (0.56); LSMD from placebo -4.2 (0.79); p=0.0000001#

\*Based on Mixed Model Repeated Measures with Multiple Imputation, with fixed categorical effects of treatment, center, study week, and treatment by study week interaction, as well as baseline value and baseline value-by-study week interaction.



## **RESILIENT PROMIS Fatigue Inventory** Key Secondary Outcome Measure





Week 14 LS mean (SE) change from baseline for TNX-102 SL -7.2 (0.55) and for placebo -4.2 (0.56); LSMD from placebo -3.0 (0.77); p=0.00009\*

<sup>#</sup>Based on Mixed Model Repeated Measures with Multiple Imputation, with fixed categorical effects of treatment, center, study week, and treatment by study week interaction, as well as baseline value and baseline value-by-study week interaction.

## **RESILIENT Sleep Quality by Daily Diary** Key Secondary Outcome Measure



#### Weekly Average of Daily Diary NRS Ratings of Prior Night Sleep Quality 0 Placebo (N=225) TNX-102 SL (N=231) -S Mean (SE) Change in NRS Sleep Quality Score -0.2 -0.4 -0.6 -0.8 -1 -1.2 -1.4 \*\*\* -1.6 \*\*\* \*\*\* \*\* -1.8 \*\*\* \*\*\* \*\*\* \*\* -2 -2.2 0 2 3 12 13 14 5 6 9 10 11 Study Week \*p<0.01; \*\*p<0.001; \*\*\*p<0.0001

Week 14 LS mean (SE) change from baseline for TNX-102 SL -1.77 (0.12) and for placebo -1.20 (0.12); LSMD from placebo -0.57 (0.17); p=0.0007#

\*Based on Mixed Model Repeated Measures with Multiple Imputation, with fixed categorical effects of treatment, center, study week, and treatment by study week interaction, as well as baseline value and baseline value-by-study week interaction.






## **RESILIENT – Cognitive Dysfunction or "Brain Fog"**

#### Brain Fog assessed by the FIQ-R<sup>1</sup> item on memory

- Patients rated their level of memory problems
- 11-pt scale going from "Good Memory" to "Very Poor Memory"
- Prespecified endpoint, but not in the "waterfall" with the key secondary endpoints
- TNX-102 SL patients vs PBO change from baseline LS mean (SE) difference of -0.8 (0.23)
- p = 0.001 (not corrected for multiple comparisons)
- Cohen's *d* effect size = 0.31



## **RESILIENT** Summary of Efficacy

#### Fibromyalgia is a *syndrome* composed of *symptoms*

- Widespread pain
- Fatigue
- Sleep disturbance

#### Efficacy across symptoms of pain, fatigue and sleep

- Pain (primary endpoint, daily pain diary): *p*-value of 0.00005
- Fatigue (PROMIS fatigue): *p*-value of 0.00009
- Sleep (PROMIS sleep disturbance): *p*-value of 0.0000001

#### Conclusion: Tonmya has "broad spectrum" or "syndromal activity"

- Broad spectrum: across several symptoms
- Syndromal: improves the syndrome (most of the symptoms)
- Potential for a broad-spectrum drug to reduce the use of multiple drugs or "polypharmacy"





## **RESILIENT** Subject Disposition





	<u>Placebo</u>	<u>TNX-102 SL</u>	<u>Total</u>
Randomized	226	231	457
Completed	<b>179</b> (79.2%)	<b>187</b> (81.0%)	<b>366</b> (80.1%)
Discontinued	<b>47</b> (20.8%)	<b>44</b> (19.0%)	<b>91</b> (19.9%)
Adverse Event	8 (3.5%)	14 (6.1%)	22 (4.8%)
Lack of Efficacy	8 (3.5%)	2 (0.9%)	10 (2.2%)
Investigator Decision	2 (0.9%)	0 (0.0%)	2 (0.4%)
Withdrew Consent	16 (7.1%)	14 (6.1%)	30 (6.6%)
Lost to Follow Up	10 (4.4%)	10 (4.3%)	20 (4.4%)
Pregnancy	0 (0.0%)	1 (0.4%)	1 (0.2%)
Non-Compliance	2 (0.9%)	3 (1.3%)	5 (1.1%)
Other	1 (0.4%)	0 (0.0%)	1 (0.2%)

© 2024 Tonix Pharmaceuticals Holding Corp.

TONIX

PHARMACEUTICALS



## **RESILIENT** Safety Summary

Among participants randomized to Tonmya<sup>™</sup> (TNX-102 SL) and to placebo, 81.0% and 79.6%, respectively, completed the study

Tonmya<sup>TM</sup> (TNX-102 SL) was generally well tolerated with an adverse event (AE) profile comparable to prior fibromyalgia studies

- No new safety signals were observed
- AE-related study discontinuations occurred in 6.1% and 3.6% of patients in the TNX-102 SL and placebo groups, respectively
- Events rated as mild or moderate made up 97.2% of AEs on placebo and 99.1% on TNX-102 SL
- As observed in prior studies with TNX-102 SL, oral administration site AEs were higher in TNX-102 SL than placebo, 42.9% and 10.2%, respectively
  - Most common oral AEs were oral hypoaesthesia, product taste abnormal, oral paraesthesia, and tongue discomfort (see table on next slide)
  - Nearly all of these common oral AEs were temporally related to dosing and lasted <60 minutes
- Serious Adverse Events (SAEs)
  - Three placebo participants experienced an SAE:
    - 1. Pneumonia, 2. Muscular weakness, and 3. Hypertension/Angina/Coronary Artery Disease
  - Two TNX-102 SL participants experienced an SAE
    - 1. Renal carcinoma deemed not related to study drug
    - 2. Acute pancreatitis with onset 14 days after completion of treatment phase, deemed 'possibly related'\* to study drug
      - Outcome: 'Recovered/Resolved'
      - \*Note: participant was non-compliant with end of treatment study visits, and the last dose before onset of SAE was not known at the time that relationship with study drug was assessed by Investigator and Sponsor





#### J'LE JAK

22

#### Treatment-Emergent Adverse Events (TEAEs) at Rate of ≥ 3% in Either Treatment Group

**RESILIENT** Safety Summary

System Organ Class Preferred Term	TNX-102 SL N=231	Placebo N=226	Total* N=457
Oral Cavity Adverse Events			
Hypoaesthesia oral	55 (23.8%)	1 (0.4%)	56 (12.3%)
Product taste abnormal	27 (11.7%)	2 (0.9%)	29 (6.3%)
Paraesthesia oral	16 (6.9%)	2 (0.9%)	18 (3.9%)
Tongue discomfort	16 (6.9%)	0 (0.0%)	16 (3.5%)
Systemic Adverse Events			
COVID-19	10 (4.3%)	7 (3.1%)	17 (3.7%)
Somnolence	7 (3.0%)	3 (1.3%)	10 (2.2%)
Headache	7 (3.0%)	4 (1.8%)	11 (2.4%)

\*Safety Population





## **RESILIENT** Demographics and Baseline Characteristics

	<b>TNX-102 SL</b> (N=231)	Placebo (N=225)
Age (years)	49.3 (10.45)*	49.5 (11.35)*
Female	224 (97.0%)†	211 (93.8%)†
Hispanic or Latino	36 (15.6%)†	35 (15.6%)†
White	194 (84.0%)†	192 (85.3%)†
Black	32 (13.9%)†	26 (11.6%)†
Pain Score (0-10 NRS)	5.9 (1.05)*	5.9 (1.08)*
Employed Yes	147 (63.6%)†	150 (66.7%)†
FM Duration (years)	8.6 (8.44)*	9.9 (9.53)*
BMI (kg/m²)	31.1 (6.34)*	31.1 (6.32)*

\* Mean (standard deviation) <sup>+</sup>N (%)





## **RESILIENT** Prior Medication Use

#### Summary of Lifetime and Prior Fibromyalgia Pharmacotherapy\*

System Organ Class Preferred Term	TNX-102 SL N=231	Placebo N=226	Total* N=457
At least one lifetime medication	124 (53.7%)	133(58.8%)	257 (56.2%)
Gabapentin/Pregabalin	72 (31.2%)	75 (33.2%)	147 (32.2%)
Gabapentin	46 (19.9%)	50 (22.1%)	96 (21.0%)
Pregabalin**	46 (19.9%)	45 (19.9%)	91 (19.9%)
Antidepressants	60 (26.0%)	66 (29.2%)	126 (27.6%)
Duloxetine**	47 (20.3%)	52 (23.0%)	99 (21.7%)
Amitriptyline	12 ( 5.2%)	13 ( 5.8%)	25 ( 5.5%)
Milnacipran**	5 ( 2.2%)	10 ( 4.4%)	15 ( 3.3%)

\*Safety population, shown are medicines >3% reported in any group \*\*Indicated for management of fibromyalgia





## **RESILIENT** Washout Medications

#### Summary of Prior Washout Medications (at least two patients)\*

System Organ Class Preferred Term	TNX-102 SL N=231	Placebo N=226	Total* N=457
At least one washout medication	14 ( 6.1%)	12 ( 5.3%)	26 ( 5.7%)
Nervous System Drug	10 ( 4.3%)	10 ( 4.4%)	20 ( 4.4%)
Gabapentin	5 ( 2.2%)	1 ( 0.4%)	6 ( 1.3%)
Amfetamine (different salts)	1 ( 0.4%)	2 ( 0.9%)	3 ( 0.7%)
Duloxetine**	1 ( 0.4%)	2 ( 0.9%)	3 ( 0.7%)
Trazodone	1 ( 0.4%)	2 ( 0.9%)	3 ( 0.7%)
Amitriptyline	0 ( 0.0%)	2 ( 0.9%)	2 ( 0.4%)

\*Safety population

\*\*Indicated for management of fibromyalgia

**CNS PORTFOLIO** 

25

## **RESILIENT** Characteristics of Study Population

#### **Pain Scores**

- Patients are asked to record "their <u>average</u> pain" for each day
  - 'Average' pain for the day will almost always be lower than 'worst' pain for a patient's day
- Baseline pain for randomization
  - a) A mean pain intensity score ≥4 and ≤9 on the 11-point (0-10) NRS scale for the 7 days immediately preceding Visit 2, and
  - b) No more than 2 individual days with a score <4 on the 7 days immediately preceding Visit 2, and
  - c) No score of 10 on any of the 7 days immediately preceding Visit 2, and
  - d) Pain scores recorded on at least 5 out of the 7 days immediately preceding Visit 2
- Mean Pain score for Baseline (BL) for the RESILIENT study was 5.9
  - Using the same method, BL for F304 (RELIEF) was 6.1 and BL for F306 (RALLY) was 6.0
- Breakthrough pain
  - No explicit rescue algorithm
  - 10 participants took an opiate during the study (6 on TNX-102 SL and 4 on placebo)




26

## **RESILIENT CSFQ-14 Females** Safety Measure







ANCOVA analysis: comparison between groups (TNX-102 SL 5.6 mg vs. Placebo) Red Diamond refers to treatment differences with p <0.05, not corrected for multiple comparisons


© 2024 Tonix Pharmaceuticals Holding Corp.



## **RESILIENT** Systolic blood pressure Safety Measure







➡ Placebo (N=226) ➡ TNX-102 SL (N=231)

Horizontal lines are the mean for each group; boxes are the 25<sup>th</sup> and 75<sup>th</sup> percentiles; and vertical lines begin and end at the 5<sup>th</sup> and 95<sup>th</sup> percentiles.

No clinically meaningful difference in mean systolic blood pressure between groups Week 14 mean (SD) change from baseline: TNX-102 SL = 0.7 (12.38) mmHg Placebo = 0.5 (10.42) mmHg




28

## **RESILIENT** Diastolic blood pressure Safety Measure







No clinically meaningful difference in mean diastolic blood pressure between groups Week 14 mean (SD) change from baseline: TNX-102 SL = 1.1 (8.60) mmHg Placebo = 0.2 (8.22) mmHg

➡ Placebo (N=226) ➡ TNX-102 SL (N=231)


Horizontal lines are the mean for each group; boxes are the 25<sup>th</sup> and 75<sup>th</sup> percentiles; and vertical lines begin and end at the 5<sup>th</sup> and 95<sup>th</sup> percentiles.



## **RESILIENT** Weight Safety Measure







No clinically meaningful difference in mean weight between treatment groups Week 14 mean (SD) change from baseline: TNX-102 SL = 0.02 (2.940) kg Placebo = 0.20 (2.932) kg

➡ Placebo (N=226) ➡ TNX-102 SL (N=231)

Horizontal lines are the mean for each group; boxes are the 25<sup>th</sup> and 75<sup>th</sup> percentiles; and vertical lines begin and end at the 5<sup>th</sup> and 95<sup>th</sup> percentiles.



## **Tonmya<sup>™</sup> (TNX-102 SL): Patents and Patent Applications**

- U.S. Composition:\*
  - A 75:25 cyclobenzaprine HCI mannitol eutectic (dependent claims add a basifying agent).
    - 5 US Patents (Expire November 2034)
    - 1 Pending US Application (Would expire November 2034)
  - A composition of a cyclobenzaprine HCl and a basifying agent suitable for sublingual absorption.
    - 1 Pending US Application (Would expire June 2033)

#### • U.S. Methods of Use\* (Specific Indications):

- Fibromyalgia
  - Pain, Sleep Disturbance, Fatigue
    - 1 Pending US Application (Would expire December 2041)
  - Early Onset Response
    - 1 Pending US Provisional Application (Would expire December 2044)
  - Depressive Symptoms
    - 1 Pending US Application (Would expire March 2032)
- Sexual Dysfunction
  - 1 Pending US Application (Would expire October 2041)
- PASC
  - 1 Pending US Application (Would expire June 2043)
- PTSD
  - 1 US Patent (Expires November 2030)
- Agitation (Dementia)
  - 1 US Patent (Expires December 2038)
  - 1 Pending US Application (Would expire December 2038)
- Alcohol Use Disorder
  - 1 Pending US Application (Would expire November 2041)

#### Foreign Filings

- Corresponding foreign patents have been filed and some have issued:
  - Composition (25 patents, 3 allowed applications, 16 pending applications)
  - Methods of Use (9 patents, 54 pending applications)

\*US Patents: Issued: US Patent Nos. 9,636,408; 9,956,188; 10,117,936; 10,864,175; 11,839,594; 9,918,948; 11,826,321. Pending: US Patent Application Nos. 13/918,692; 18/385,468; 13/412,571; 18/265,525; 63/612,352; 18/382,262; 18/037,815; 17/226,058; 18/212,500.



## **Fibromyalgia: Market Characteristics**

#### Prevalence

• One of the more common chronic pain disorders (2-4% of US Population)<sup>1</sup>

### **Diagnosed population**

- Large population but underdiagnosed<sup>2</sup> relative to prevalence rate
- Majority receive drug treatment<sup>3</sup>

### **Treatment Pattern**

- Polypharmacy the norm average 2.6 drugs/patient<sup>3</sup>
- Rotation through therapy common: average ~5 drugs/year<sup>3</sup>
- Estimated that >22 million prescriptions are issued for the treatment of fibromyalgia (on- and off-label usage) each year<sup>4,5</sup>

## **Unmet Need**

• Majority of patients do not respond or cannot tolerate therapy<sup>6</sup>


<sup>1</sup>American College of Rheumatology (<u>www.ACRPatientInfo.org</u> accessed May 7, 2019) – prevalence rate of 2-4% for U.S. adult population (~250 million)
 <sup>2</sup>Vincent et al., 2013; diagnosed prevalence rate was 1.1% of adult population or 50% of the prevalent population
 <sup>3</sup>Robinson, et al., 2012; 85% received drug treatment
 <sup>4</sup>Vincent et al, Arthritis Care Res 2013;65:786
 <sup>5</sup>Product sales derived from IMS MIDAS; IMS NDTI used to factor usage for fibromyalgia; data accessed April 2015.
 <sup>6</sup>Market research by Frost & Sullivan, commissioned by Tonix, 2011



32

## Fewer than Half of Those Treated for Fibromyalgia Receive Sustained Benefit from the Three FDA-Approved Drugs<sup>1</sup>

- The treatment objective is to restore functionality and quality of life by broadly improving symptoms while avoiding significant side effects
- The majority fail therapy due to lack of a response or poor tolerability<sup>2</sup>



<sup>1</sup> The three drugs with FDA approval for the treatment of fibromyalgia: Pregabalin (Lyrica); Duloxetine (Cymbalta); Milnacipran (Savella) <sup>2</sup> Market research by Frost & Sullivan, commissioned by Tonix (2011)



## Current FDA-Approved Fibromyalgia Drugs were Repurposed<sup>1</sup>

#### Human investigation was required to find drugs that improve pain in fibromyalgia

• No current product addresses pain, poor sleep and fatigue

Drug		Lyrica® - Pfizer	Cymbalta® - Lilly Savella® - AbbVie	
Initial Indication	Sought	Epilepsy	Depression	
Class		Gabapentinoid	SNRI	
Mechanism		Slow neuron firing	Block NE reuptake	
	Pain	+	+	
Fibromyalgia Activity	Sleep	+	-	
	Fatigue	-	+	
	Sleep	-	+	
	Fatigue	+	-	
Tolerability Issues		Weight gain	Blood Pressure increases	
			Sexual function impairment	
			Glissues	

<sup>1</sup>The three drugs with FDA approval for the treatment of fibromyalgia: Pregabalin (Lyrica); Duloxetine (Cymbalta); Milnacipran (Savella)

34

## Large Need for New Fibromyalgia Therapies that Provide Broad Symptom Improvement with Better Tolerability

- Currently-approved medications may have side effects that limit long-term use<sup>1</sup>
  - Many patients skip doses or discontinue altogether within months of treatment initiation
- Medication-related side effects may be similar to fibromyalgia symptoms
- High rates of discontinuation, switching and augmentation
  - Attempt to treat multiple symptoms and/or avoid intolerable side effects
  - Average of 2-3 medications used simultaneously<sup>2</sup>
  - The typical patient has tried six different medications<sup>3</sup>
- Substantial off-label use of narcotic painkillers and prescription sleep aids<sup>3</sup>
  - Among those diagnosed, more than one-third have used prescription opioids as a means of treatment<sup>4</sup>
- Tonmya<sup>™</sup> (TNX-102 SL) is a non-opioid, centrally-acting analgesic that could provide a new therapeutic option for fibromyalgia patients

© 2024 Tonix Pharmaceuticals Holding Corp.

## **Tonmya<sup>™</sup> Showed Broad-Spectrum Activity and was Well Tolerated**

		Lyrica®	Cymbalta® Savella®	Tonmya™
Activity	Pain	YES	YES	YES
	Sleep	YES	-	YES
	Fatigue	-	YES	YES

	Insomnia	-	+	-
	Fatigue	+	-	-
Systemic Tolerability	Weight	+	-	-
Issues	Blood Pressure	-	+	-
	Sexual function	-	+	-
	GI issues	-	+	-

- Tonmya showed activity in all three measures of pain, sleep, and fatigue
- Tonmya is not associated with any of the commonly reported side effects



36

# ~50% of U.S. Fibromyalgia Patients are on Medicare: Prescription Coverage in Medicare Stands to Benefit from Changes in IRA

# Approximately 50% of fibromyalgia patients are on Medicare

 EVERSANA analysis of claims database consisting of 2.2M patients, for which 1.2M claims were submitted throughout March 2002-March 2023<sup>1</sup>


# Beneficial Changes in 2025 to Medicare Part D through Inflation Reduction Act (IRA)<sup>2</sup>

- Medicare prescription payment plan to offer enrollees the option to pay out-of-pocket prescription drug costs in the form of capped monthly installment payments instead of all at once at the pharmacy
- Annual out-of-pocket costs will be capped at \$2,000 in year 2025
- Will replace the existing Coverage Gap Discount Program, which sunsets as of January 1, 2025

<sup>1</sup>EVERSANA analysis of claims database, May 2024; commissioned by Tonix <sup>2</sup>Source: <u>Final CY 2025 Part D Redesign Program Instructions Fact Sheet | CMS</u>

#### Fibromyalgia Patients by Coverage<sup>1</sup>

# **Insurance Distribution**




TONIX


**CNS PORTFOLIC** 

## Prescribers Interviewed are Broadly Dissatisfied with Available Fibromyalgia Medications: Results of Primary Research<sup>1</sup>

Perspectives on FM Therapies from Prescribers Interviewed						
Drug	Positives	Negatives				
<b>Duloxetine</b> (Cymbalta, generic)	<ul> <li>Relatively high efficacy (compared to alternatives)</li> <li>Can be titrated slowly from 20mg to 120mg</li> </ul>	<ul> <li>Tolerability issues: worsening depression, insomnia</li> <li>Seldom used as a monotherapy; often requires adjunct</li> </ul>				
<b>Pregabalin</b> (Lyrica, generic)	<ul> <li>Relatively high efficacy (compared to alternatives)</li> <li>Can often be safely combined with other medications</li> </ul>	<ul> <li>Suboptimal for long-term use (e.g., weight gain)</li> <li>Schedule V status makes some HCPs more cautious to Rx</li> </ul>				
Savella (milnacipran)	Offers another option if patient fails Cymbalta or Lyrica	<ul> <li>Subpar efficacy does not counterbalance tolerability issues</li> <li>High cost and access constraints (~\$50/month)</li> </ul>				
<b>Cyclobenzaprine</b> (Flexeril, generic; oral formulation, off- label)	<ul> <li>Active for initiating and sustaining sleep; can be titrated up</li> <li>Active for pain driven by stiffness and muscle spasms</li> </ul>	<ul> <li>Mixed perspectives on pain benefit independent of sleep</li> <li>Suboptimal long-term results as efficacy wanes</li> </ul>				



<sup>1</sup> EVERSANA primary physician research, May 2024; commissioned by Tonix





© 2024 Tonix Pharmaceuticals Holding Corp.

# **Opportunity for a New, Unique Fibromyalgia Treatment Option: Results of Primary Research from EVERSANA**<sup>1,2</sup>


		<ul> <li>Prescribers indicate a very high unmet need in FM (ranked ≥4.0 on a 5-point scale)</li> </ul>
		<ul> <li>Prescribers report there is no standard of care in FM, employ an individualized approach based on symptomology</li> </ul>
	FM Landscape	No new treatments approved since 2009
		Prescribers report minimal promotional activities by any pharmaceutical company
		<ul> <li>Highly concentrated prescriber base with 50% of patients treated by ~16k physicians</li> </ul>
		<ul> <li>Physicians reacted positively to Tonmya's efficacy and safety profile (based on Phase 3 Study results)</li> </ul>
	Physician Primary	<ul> <li>Median interest = 4.0 on a 5-point scale</li> </ul>
	Market Research	<ul> <li>Driving attributes included strong efficacy, safety and tolerability</li> </ul>
		<ul> <li>Unique &amp; differentiating efficacy features included improvements in sleep and fatigue</li> </ul>
$\square$		<ul> <li>Physicians indicated intended use in 40% of their FM patients</li> </ul>
	Anticipated Use	<ul> <li>Majority of respondents indicated Tonmya would be their first choice, if accessible</li> </ul>
	Anticipated 03e	<ul> <li>Physicians surveyed indicated they are well-equipped to deal with access restrictions including prior authorizations and step-edits</li> </ul>

<sup>1</sup> EVERSANA primary physician research, May 2024; commissioned by Tonix <sup>2</sup> EVERSANA analysis of claims database, May 2024; commissioned by Tonix



39

# Many Fibromyalgia Patients are Prescribed Off-Label Drugs; ~53% FM Patients Prescribed Opioids Off-Label<sup>1,2</sup>



CNS PORTFOLIO

<sup>1</sup> 2022-2023

<sup>2</sup> EVERSANA analysis of claims database, May 2024; commissioned by Tonix

<sup>3</sup>Index date refers to date when ICD10 code was entered into database

TONIX PHARMACEUTICALS

40

## Potential for Tonix to Launch and Market Tonmya<sup>™</sup>

#### Decline in personal promotion ("Detailing") of prescription drugs

- The pandemic accelerated transition to non-personal promotion
  - Omnichannel is more important and more sophisticated
    - Tele-sales
    - Digital
    - Direct mail
- Growth in need to support patients with payers to seek reimbursement

#### Fibromyalgia experts are a subset of Rheumatologists

- New prescriptions for fibromyalgia drugs originate in a subset of doctors
  - Refills may be written by general practitioners

#### Channels for distribution of prescription drugs are evolving

• Growth of specialty pharmacies who distribute products by mail



#### Planning for Tonmya<sup>™</sup> Launch and Marketing

#### Several companies that successfully developed CNS drugs have launched them

• Big Pharma wants the commercial launch de-risked before acquisition (*e.g.*, Nurtec®)

Company		Mkt Cap¹	Product	Indication	FDA Approval	Exit
Axsome	AXSM	\$4.4 B	Auvelity®	Depression	8/2022	
Biohaven	BHVN	\$3.8 B	Nurtec®	Migraine	2/2020	Sold to PFE for \$12 B in Oct 2022
IntraCellular	ITCI	\$7.1 B	Caplyta®	Schizophrenia	12/2019	
Supernus	SUPN	\$1.5 B	Oxtella-XR®	Seizures	1/2019	
Neurocrine	NBIX	\$13.2 B	Ingrezza®	Tardive Dyskinesia	4/2017	
Acadia	ACAD	\$4.1 B	Nuplazid®	Parkinson's psychosis	4/2016	

To prepare for the launch of Tonmya, Tonix acquired two marketed Rx drugs: Zembrace® and Tosymra®

• Both are indicated for the acute treatment of migraine

**CNS PORTFOLIO** 

# About Cyclobenzaprine and Tonmya<sup>™</sup> Formulation



43

© 2024 Tonix Pharmaceuticals Holding Corp.

#### **Cyclobenzaprine Long-Term Utilization**

H<sub>3</sub>C

- Flexeril® approved in 1977 by Merck for the treatment of muscle spasm
  - 10 mg T.I.D. for acute use (2-3 weeks)
  - 1999 OTC AdCom Briefing Package: original NDA included "8 long term safety studies in which patients with various neurologic disorders received cyclobenzaprine up to 80 mg per day for 1 month up to 3 years."

#### 6 published studies in fibromyalgia

- N=246, placebo controlled, 4-24 week treatment period
- Generally well tolerated, no new or unexpected AEs

#### Extensive safety record in humans for over 30 years

- In recent years, ~20 million prescriptions and ~ 1 billion tablets dispensed per year
- Chronic cyclobenzaprine use is common (~12% of users)
- Post-marketing surveillance program
  - 7,607 patients included 297 patients treated with 10 mgs for  $\geq$  30 days
  - Incidence of most common AEs was much lower than in controlled studies








#### **Tonmya<sup>™</sup> (TNX-102 SL): Proprietary Eutectic Formulation**


Proprietary Cyclobenzaprine HCL Eutectic Mixture Stabilizes Sublingual Tablet Formulation






#### **TNX-102 SL: Sublingual Administration and Transmucosal Delivery**

- Advantages of the sublingual route
- Faster absorption provides PK that is ideal for bedtime dosing
- Bypasses "first-pass" hepatic metabolism
- Reduced metabolism of parent CBP to active metabolite norcyclobenzaprine (nCBP)




# Formulation with Base Increases Systemic Absorption of Sublingual Cyclobenzaprine<sup>1</sup>

# Concentration gradient increases diffusion of free base across oral mucosa (Le Chatelier's Principle)



# Tonmya<sup>™</sup> (TNX-102 SL): Cyclobenzaprine Detected in Plasma Within Minutes Following Sublingual Administration

Plasma Concentration Versus Time of TNX-102 SL Compared to Cyclobenzaprine IR



**CNS PORTFOLIO** 



# Tonmya<sup>™</sup> (TNX-102 SL): Single Dose PK Differentiation from Oral IR CBP

#### TNX-102 SL 2.8 mg v. Oral IR CBP 5 mg: Single Dose Pharmacokinetics

Parameter	TNX-102 SL 2.8 mg	Oral IR CBP 5 mg	TNX-102 SL Compared to	
	Cycloben	Oral IR		
Absorption Lag Time	0.050 hr (3 min)	0.622 hr (37 min)	12x faster	
Relative Bioavailability	154%	-	54% higher	
C <sub>max</sub>	3.41 ng/mL 4.26 ng/mL		20% lower	
AUC <sub>0-48</sub>	57.4 ng∙hr/mL	69.5 ng∙hr/mL	17% lower	
	Norcyclobe			
C <sub>max</sub>	0.81 ng/mL	0.81 ng/mL 1.71 ng/mL		
AUC <sub>0-48</sub>	30.5 ng•hr/mL 58.6 ng•hr/mL		48% lower	
	Cyclobenzaprine/N			
Ratio AUC <sub>0-48</sub>	1.88	1.18	59% higher	

PK = pharmacokinetics

IR = immediate release

CBP = cyclobenzaprine

C<sub>max</sub> = maximum concentration

AUC = Area under the curve

# Tonmya<sup>™</sup> (TNX-102 SL): Multi-Dose PK Differentiation from Simulated Oral IR CBP


# Tonmya<sup>™</sup> (TNX-102 SL): Proprietary sublingual formulation of cyclobenzaprine (CBP) with transmucosal absorption


- Rapid systemic exposure
- Increases bioavailability during sleep
- Avoids first-pass metabolism
- Lowers exposure to long-lived active major metabolite, norcyclobenzaprine (norCBP)

# CBP undergoes extensive first-pass hepatic metabolism when orally ingested


Active major metabolite, norCBP

PK = pharmacokinetics IR = immediate release CBP = Cyclo = cyclobenzaprine Nor = norCBP = norcyclobenzaprine Steady State Pharmacokinetics (after 20 days dosing)





Day 20 TNX-102 SL 5.6 mg v. Simulated Oral IR 10 mg





# Multi-Functional Mechanism Involves Antagonism at Four Neuronal Receptors

#### Active ingredient, cyclobenzaprine, interacts with four receptors

- Antagonist at 5-HT<sub>2A</sub> receptors
  - Similar activity to trazodone and Nuplazid<sup>®</sup> (pimivanserin)
- Antagonist at  $\alpha_1$ -adrenergic receptor
  - Similar activity to Prazosin® (prazosin)
- Antagonist at histamine H<sub>1</sub> receptors
  - Similar activity to Benadryl® (diphenhydramine) and hydroxyzine
- Antagonist at muscarinic M<sub>1</sub> receptors
  - Similar activity to Benadryl<sup>®</sup> (diphenhydramine), Prozac<sup>®</sup> (fluoxetine), Paxil<sup>®</sup> (paroxetine), Zyprexa (olanzapine) and Seroquel<sup>®</sup> (quetiapine).





## **Cyclobenzaprine Binding Affinities for Receptor and Transporter**

	H <sub>1</sub>	5-HT <sub>2A</sub>	α <sub>1Α</sub>	α <sub>1Β</sub>	M <sub>1</sub>	SERT	NET
Cyclobenzaprine (CBP)	1.2	5.4	7.1	8	8.4	29	39
Norcyclobenzaprine (nCBP)	17.8	38	82	71	155	461	12.8

CBP/nCBP Activity	Antagonist	Inhibitor
-------------------	------------	-----------




© 2024 Tonix Pharmaceuticals Holding Corp.

#### **Cyclobenzaprine Effects on Nerve Cell Signaling**

#### Cyclobenzaprine is a multi-functional drug – SNARI

- inhibits serotonin and norepinephrine reuptake
- blocks serotonin 5-HT<sub>2A</sub> and norepinephrine<sub> $\alpha_1$ </sub> receptors



53

**CNS PORTFOLIC** 

54

# Tonmya<sup>™</sup> (TNX-102 SL): No Recognized Abuse Potential in Clinical Studies

Active ingredient is cyclobenzaprine, which is structurally related to tricyclic antidepressants

- Cyclobenzaprine interacts with receptors that regulate sleep quality: 5-HT2A, α1-adrenergic and histamine H1 receptors
- Cyclobenzaprine does NOT interact with the same receptors as traditional hypnotic sleep drugs, benzodiazepines or non- benzodiazepines that are associated with retrograde amnesia
- Cyclobenzaprine-containing product was approved 40 years ago and current labeling (May 2016) indicates no abuse or dependence concern

Tonmya<sup>™</sup> (TNX-102 SL) NDA can be filed without drug abuse and dependency assessment studies

• April 2017 meeting minutes from the March 2017 FDA meeting



# Tonmya<sup>™</sup> (TNX-102 SL): Sublingual Formulation is Designed for Bedtime Administration

Tonmya™ (TNX-102 SL): Proprietary sublingual formulation of cyclobenzaprine (CBP) with transmucosal absorption

- Innovation by design with patent protected CBP/mannitol eutectic
- Rapid systemic exposure
- Increases bioavailability during sleep
- Avoids first-pass metabolism
- Lowers exposure to long-lived active major metabolite, norcyclobenzaprine (norCBP)

#### CBP undergoes extensive first-pass hepatic metabolism when orally ingested

- Active major metabolite, norCBP1
- Long half-life (~72 hours)
- Less selective for target receptors (5-HT2A, α1-adrenergic, histamine H1)
- More selective for norepinephrine transporter and muscarinic M1

#### Multi-functional activity suggests potential for other indications

- TNX-102 SL was developed for the management of fibromyalgia (Phase 3)
- Sleep quality is a problem in other conditions



# Tonmya<sup>™</sup> for Other Indications: Long COVID and Acute Stress Disorder



© 2024 Tonix Pharmaceuticals Holding Corp.



## About Fibromyalgia-Type Long COVID

Long COVID is broadly defined as signs, symptoms, and conditions that continue or develop after acute COVID-19 infection<sup>1</sup>



#### Many Long-COVID symptoms overlap with core symptoms of fibromyalgia

and are hallmarks of other chronic pain syndromes like myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)

19% Long COVID occurs in approximately 19% of recovered COVID-19 patients<sup>2</sup>
 40% As many as 40% of Long COVID patients experience multi-site pain<sup>3,4</sup>

<sup>1</sup>CDC - <u>https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html#:~:text=Some%20people%20who%20have%20been,after%20acute%20COVID%2D19%20infection <sup>2</sup>CDC Press Release, June 22, 2022 - <u>https://www.cdc.gov/nchs/pressroom/nchs\_press\_releases/2022/20220622.htm</u></u>

<sup>3</sup>Harris, H, et al. Tonix data on file. 2022 <sup>4</sup>TriNetX Analytics

© 2024 Tonix Pharmaceuticals Holding Corp.



57

## TNX-102 SL for Fibromyalgia-Type Long COVID: Phase 2 PREVAIL Study Design




#### **Study characteristics:**

- Randomized, double-blind, placebo-controlled study of TNX-102 SL in fibromyalgia-type Long COVID
- U.S. sites only, *completed enrollment of 63 patients*

#### **Primary Endpoint:**

- Daily diary pain severity score change from baseline to Week 14 (TNX-102 SL vs. placebo)
  - Weekly averages of the daily numerical rating scale scores



# Next Steps: End of Phase 2 Meeting with FDA

58

CNS PORTFOLIC

#### **TNX-102 SL: Phase 2 PREVAIL Topline Results<sup>1</sup>**

Did not meet the primary endpoint of multi-site pain reduction at Week 14

However, findings fulfill the objectives of proof-of-concept study, supporting the decision to advance the program based on a proposed primary endpoint using the PROMIS Fatigue scale

- TNX-102 SL showed robust effect size in improving fatigue and consistent activity across secondary measures of sleep quality, cognitive function, disability and Patient Global Impression of Change (PGIC)
- Was generally well tolerated with an adverse event (AE) profile comparable to prior studies with TNX-102 SL:
  - AE-related discontinuations were similar in drug and placebo arms
  - No new safety signals were observed

#### Fatigue is the signature symptom of Long COVID and has been identified as the dominant symptom contributing to disability<sup>2</sup>

- We observed numerical improvement in the PROMIS fatigue score (in RELIEF p=0.007 MMRM and in RALLY p=0.007 MMRM) in both prior Phase 3 studies of TNX-102 SL in fibromyalgia,
- We believe the results of PREVAIL, together with extensive data from studies in other chronic conditions<sup>3-5</sup>, makes PROMIS Fatigue a solid candidate for the primary endpoint of future Long COVID registrational studies

<sup>1</sup>Tonix Press Release, September 5, 2023 - <u>https://bit.ly/3Z6FQHQ</u> <sup>2</sup>Walker S, *et al. BMJ Open* 2023;13:e069217. doi:10.1136/ bmjopen-2022-069217 <sup>3</sup>Cook, K.F., et al. 2016. *Journal of Clinical Epidemiology*, 73, 89- 102 <sup>4</sup>Cella, D., et al. 2016. *Journal of Clinical Epidemiology*, 73, 128–134 <sup>5</sup>Lai, J.S., et al. 2011. *Archives of Physical Medicine and Rehabilitation*, 92(10 Supplement), S20-S27.



## Acute Stress Reaction (ASR)/ Acute Stress Disorder (ASD)

ASR/ASD are acute stress conditions resulting from trauma which can affect both civilian and military populations.

Large unmet need:

- According to National Center for PTSD, about 60% of men and 50% of women in the US are exposed least one traumatic experience in their lives<sup>1</sup>
- In the US alone, one-third of emergency department visits (40-50 million patients per year) are for evaluation after trauma exposures<sup>2</sup>

#### **Current standard of care:**

 No medications are currently available at or near the point of care to treat patients suffering from acute traumatic events and support long-term health



# CNS PORTFOLIC

# **TNX-102 SL for ASR/ASD: Program Status**

#### Status: Expect to start Phase 2 in 2Q 2024

#### Phase 2 Trial Funded by DoD grant to University of North Carolina (UNC)

- UNC Institute for Trauma Recovery awarded a \$3M grant from the Department of Defense (DoD)
- OASIS trial will build upon infrastructure developed through the UNC-led, \$40M AURORA initiative
  - AURORA study is a major national research initiative to improve the understanding, prevention, and recovery of individuals who have experienced a traumatic event
  - Supported in part by funding from the National Institutes of Health (NIH) and the health care arm of Google's parent company Alphabet
- Opportunity to investigate the correlation between motor vehicle collisions and the emergence of ASD and PTSD
- Supported by multiple clinical trials:
  - Phase 2 trial in military-related PTSD (AtEase or NCT02277704)
  - Phase 3 trial in military-related PTSD (HONOR or NCT03062540)
  - Phase 3 trial in primarily civilian PTSD (RECOVERY or NCT03841773)
- In each of these studies, early and sustained improvements in sleep were associated with TNX-102 SL treatment by the PROMIS sleep disturbance (SD) scale and the Clinician Administered PTSD Scale (CAPS-5) "sleep disturbance" item.

# Together these studies provide preliminary evidence that TNX-102 SL is well-tolerated and may promote recovery from PTSD via a pharmacodynamic facilitation of sleep-dependent emotional memory processing



## TNX-102 SL for ASR/ASD: Phase 2 OASIS Study Design

#### General study characteristics:

- Randomized, double-blind, placebo-controlled study in Acute Stress Reaction (ASR) / Acute Stress Disorder (ASD)
- The proposed <u>Optimizing Acute Stress reaction Interventions with TNX-102 SL</u> (OASIS) trial will examine the safety and efficacy of TNX-102 SL to reduce adverse posttraumatic neuropsychiatric sequelae among patients presenting to the emergency department after a motor vehicle collision (MVC)
- The trial will enroll approximately 180 individuals who acutely experienced trauma at study sites across the US
- Participants will be randomized in the emergency department to receive a two-week course of either TNX-102 SL or placebo
- Investigator-initiated IND

#### **Objective:**

- Investigate the potential of Tonix's TNX-102 SL (cyclobenzaprine HCl sublingual tablets) to reduce the frequency and severity of the adverse effects of traumatic exposure, including acute stress reaction (ASR), acute stress disorder (ASD), and posttraumatic stress disorder (PTSD).
- ASR refers to the body's immediate response to trauma, whereas ASD is the short-term effects of trauma (within 1 month), and PTSD is the long-term effects of trauma (beyond 1 month)

# **TNX-102 SL once-daily at bedtime** 5.6 mg (2 x 2.8 mg tablets)\*

#### Placebo once-daily at bedtime

2 weeks

\*First dose of TNX-102 SL 5.6 mg versus placebo taken in the emergency department, and then daily at bedtime to finish 2 weeks of treatment

# A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With ASR/ ASD (OASIS)

- Primary outcome measure: Acute Stress Disorder Scale (ASDS) assessed at 7 and 21 days post MVC
- Posttraumatic stress symptom severity assessed at 6 and 12 weeks post MVC using the PTSD Checklist for DSM-5 (PCL-5)
- Standardized survey instruments of sleep disturbances, anxiety and depression symptoms, general physical and mental health, and clinical global improvement also employed
- Detailed and brief neurocognitive assessments are performed from baseline to 12 weeks after MVC at specific timepoints throughout study participation period



# **THANK YOU**

# APPENDIX



© 2023 Tonix Pharmaceuticals Holding Corp.

## Tonmya<sup>™</sup> (TNX-102 SL): RALLY Study Increased Adverse Event-Related Discontinuations

Increases in AE-Related discontinuations in RALLY study compared with RELIEF study in both placebo and TNX-102 SL groups

	RALLY (F306)	RELIEF (F304)	RALLY (F306)	RELIEF (F304)
	Plac	cebo	TNX-102 SL	
Patients with at least one TEAE leading to early discontinuation	6.2%	3.5%	15.2%	8.5%
Ratio of patients with at least one TEAE leading to early discontinuation in F306 to F304 (F306/F304)	1.77		1.79	

TEAE = treatment-emergent adverse event

#### **Adverse events in RALLY**

- TNX-102 SL 5.6 mg was well tolerated.
- Among participants randomized to drug and placebo groups, 73.8% and 81.4%, respectively, completed the 14-week dosing period.
- As expected, based on prior TNX-102 SL studies, oral administration site reactions were higher in the drug treatment group, including rates of tongue/mouth numbness, pain/discomfort of tongue/mouth, and product taste abnormal (typically a transient bitter aftertaste)
- Tongue/mouth numbress or tingling and product aftertaste were local effects nearly always temporally related to dose administration and transiently expressed (<60 minutes) in most occurrences.</li>
- Adverse events resulted in premature study discontinuation in TNX-102 SL and placebo groups at rates of 15.2% and 6.2%, respectively
- Approximately 95% of adverse events in both the drug treatment and placebo groups were rated as mild or moderate.



## Tonmya<sup>™</sup> (TNX-102 SL): RALLY Study Impact of Missing Data on *p*-Values in RALLY

- Since 2010, FDA has generally required that "missing data" be accounted for by using a statistical method called "multiple imputation" or MI
  - MI data approach can attenuate *p*-values in the setting of missing data
- RALLY (F306) results without MI treatment for missing data are comparable to prior statistically significant RELIEF (F304) study
- Efficacy results in the table without MI are labelled "MMRM"

# MI missing data treatment attenuated *p*-values in RALLY

 At the current time, we expect MI will be part of the statistical analysis for the RESILIENT trial

	RALLY (F306)			
	MMRM	+MI*	MMRM**	
Endpoints	LSMD (SE)	<i>p</i> -value	LSMD (SE)	<i>p</i> -value
Pain by Diary <sup>#</sup>	-0.2 (0.16)	0.115	-0.4 (0.16)	0.014
FIQR Symptom domain	-1.9 (1.52)	0.216	-3.4 (1.55)	0.030
FIQR Function domain	-0.4 (1.46)	0.797	-1.6 (1.48)	0.266
<b>PROMIS Sleep Disturbance</b>	-2.3 (0.80)	0.004	-3.3 (0.73)	<0.001
PROMIS Fatigue	-1.2 (0.74)	0.101	-2.0 (0.73)	0.007
Sleep Quality by Diary	-0.3 (0.16)	0.094	-0.4 (0.16)	0.008
		RELIEF	(F304)	
	MMRM	+MI*	MMRI	N**
Endpoints	LSMD (SE)	LSMD (SE) p-value		<i>p</i> -value
Pain by Diary <sup>#</sup>	-0.4 (0.16)	0.010	-0.5 (0.16)	0.004
FIQR Symptom domain	-4.3 (1.60)	0.007	-5.6 (1.60)	<0.001
FIQR Function domain	-4.4 (1.69)	0.009	-5.2 (1.63)	0.001
PROMIS Sleep Disturbance	-2.9 (0.82)	<0.001	-3.3 (0.82)	<0.001
PROMIS Fatigue	-1.8 (0.76)	0.018	-2.1 (0.79)	0.007
Sleep Quality by Diary	-0.6 (0.17)	<0.001	-0.7 (0.17)	<0.001

FIQR = Fibromyalgia Impact Questionnaire-Revised; LSMD = least squares mean difference (between TNX-102 SL and placebo); MMRM = mixed model repeated measures; MI = multiple imputation; PROMIS = Patient-Reported Outcomes Measurement Information System; SE = standard error

\* MMRM with MI was the pre-specified primary analysis

\*\*MMRM without MI was a pre-specified analysis


<sup>#</sup> Primary efficacy endpoint: change from baseline in the weekly average of daily diary pain severity numerical rating scale scores



## **Chronic Overlapping Pain Conditions (COPC) Believed to Result from Shared Brain Processes**

 COPC is a set of disorders that coaggregate; these disorders can include but are not limited to<sup>1,2</sup>:

- Temporomandibular disorder
- Fibromyalgia
- Irritable bowel syndrome
- Vulvodynia
- CFS/ME<sup>3</sup>
- Interstitial cystitis/painful bladder syndrome



- Endometriosis
- Chronic tension-type headache
- Migraine headache
- Chronic lower back pain

 Similar central mechanisms play significant roles in all pain conditions, even those with known peripheral contributions<sup>1,2</sup>

<sup>1</sup>Maixner W, et al. *J Pain*. 2016;17(9 Suppl):T93-T107. <sup>2</sup>Veasley C, et al. http://www.chronicpainresearch.org/public/CPRA\_WhitePaper\_2015-FINAL-Digital.pdf. Published May 2015. Accessed July 26, 2021. <sup>3</sup>CFS/ME – chronic fatigue syndrome/myalgic encephalomyelitis



© 2024 Tonix Pharmaceuticals Holding Corp.

# Role of Infections in Triggering Fibromyalgia or Chronic fatigue (CFS)-Like Illnesses

- Symptoms of Long COVID, like multi-site pain, fatigue and insomnia, are the hallmarks of chronic pain syndromes like fibromyalgia and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).
- In August 2022, the HHS released the *National Research Action Plan on Long COVID*<sup>1</sup> which endorses the connection between Long COVID and chronic fatigue syndrome.

# Infection initiates an autoreactive process, which affects several functions, including brain and energy metabolism<sup>2-7</sup>

- Infections can trigger any of these conditions in approximately 10% of exposed individuals
- The initial location of the infection determines the subsequent pain syndrome
- Any type of infectious diarrhea will trigger irritable bowel syndrome (IBS) in 10% to 20% of those exposed

<sup>1</sup>Department of Health and Human Services, Office of the Assistant Secretary for Health. 2022. National Research Action Plan on Long COVID, 200 Independence Ave SW, Washington, DC 20201. <sup>2</sup>Blomberg J, et al. Front Immunol. 2018;9:229. Published 2018 Feb 15.

<sup>3</sup>Warren JW, et al. Urology. 2008;71(6):1085-1090.

<sup>4</sup>Buskila D, et al. Autoimmun Rev. 2008;8(1):41-43.

<sup>5</sup>Hickie I, et al. BMJ. 2006;333(7568):575.

<sup>6</sup>Parry SD, et al. Am J Gastroenterol. 2003;98(9):1970-1975. <sup>7</sup>Halvorson HA, et al. Am J Gastroenterol. 2006;101(8):1894-1942.



CNS PORTFOLIC

## The Third Type of Pain: Nociplastic Pain<sup>1</sup>

#### Nociplastic syndrome includes: (1) widespread pain (2)fatigue **Nociplastic Pain Pathological Pain** (3)sleep disturbances (4) cognitive dysfunction ("brain fog") Examples: Mechanism: Fibromyalgia Altered pain ME/CFS perception in the Migraine brain Functionally rritable Bowel **Appropriate Pain if** Syndrome Endometriosis Acute Low Back Pain **Nociceptive Pain Neuropathic Pain** Mechanism: Examples: Examples: Mechanism: Impingement, Sciatica Stubbed toe Actual or lesion or Shingles Appendicitis threatened inflammation of damage to tissue nerve

CNS PORTFOLIO

## Fibromyalgia is Believed to Result from Chronic Pain or Prior Stress Experiences

The pain system evolved to detect acute pain

• The body's "check engine" light

Chronic pain breaks down the system that determines whether a sensory experience is painful

- Chronic pain results in nociplastic syndromes
- Nociplastic syndrome was formerly known as "Central and Peripheral Sensitization"

#### Chronic Overlapping Pain Conditions (COPCs) are Nociplastic Syndromes:

- Fibromyalgia
- ME/CFS
- Migraine
- Irritable Bowel Syndrome
- Endometriosis
- Low Back Pain

Stresses that may precede or precipitate FM include:

Chronic nociceptive pain

- *e.g.*, osteoarthritis Chronic neuropathic pain
- *e.g.*, diabetic neuropathy Infectious
- *e.g.*, viral illness Cancer
- *e.g.*, breast cancer Chemical
- e.g., cancer chemotherapy Traumatic
- *e.g.*, motor vehicle accident Physiologic
  - e.g., disturbed sleep



### **Common Chronic Conditions are a Challenge for Pharma**

#### Fibromyalgia is a common chronic disease<sup>1</sup>

• Chronic pain syndrome that persists for years or decades

#### No animal model is recognized for nociplastic syndromes or its component symptoms

- Widespread pain
- Fatigue
- Sleep disturbance
- Cognitive impairment

#### Nociplastic symptoms are subjective

· Humans need to report symptoms using scales

#### Clinical trials measuring subjective symptoms are challenging

- Placebo response is typically observed
- Long-term therapy means requires long-term tolerability





## **Common Chronic Conditions are a Challenge for Society**

The Opiate Crisis in the U.S. was driven by mistreatment of chronic pain, which was often nociplastic pain

- The epidemic of prescription pain killers was addressed by regulations which limited the availability of opiates
- Mandy individuals who are opiate dependent have transitioned to illegal street heroin and fentanyl
- Illegal drugs contribute to homelessness


There is an unmet need for non-opiate analgesics that address nociplastic pain

No new drug for fibromyalgia has been approved since 2009



# **Central Sensitization (CS) A Feature of Many Nociplastic Pain Syndromes**


- CS is caused by amplified neural signaling in CNS pain circuits<sup>1-3</sup>
- Patients with CS perceive higher pain to a slightly noxious stimuli than in non-CS individuals (hyperalgesia)<sup>1</sup>
- Severe CS can lead to hypersensitivity to stimuli that are not typically painful (allodynia)<sup>2</sup>
- CS varies in severity and is observed in syndromes including FM and ME/CFS<sup>1,3</sup>






73

## **Central Sensitization (CS) Can Occur in a Range of Diseases and Conditions**





**CNS PORTFOLIO**